Can a once-weekly antibiotic help people with opioid use disorder beat serious infections at home?
NCT ID NCT05521880
First seen Jul 24, 2026 ยท Last updated Jul 24, 2026
Summary
This trial tests whether a weekly IV antibiotic called oritavancin, given alongside medication for opioid use disorder, can help people finish treatment for serious infections like bloodstream or bone infections without needing to stay in a nursing facility. The study enrolls adults hospitalized with a drug-related infection who are stable enough to go home. Participants receive oritavancin doses at a clinic that also provides opioid treatment and peer support, and are followed for 12 weeks to see if the infection clears.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an antibiotic called oritavancin given weekly by IV
- What this could lead to
- If it works, this approach could offer a way for people with opioid use disorder to complete treatment for serious infections at home rather than in a nursing facility.
- What could go wrong
- This is a very small early-phase trial with only one participant enrolled, so results may not apply broadly. The infection may not respond to oritavancin, or patients may struggle to stay in treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
1 person
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 88 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years old * Able and willing to sign consent * Ongoing opioid use defined by self report of use of non prescription opioids within 3 months of hospitalization * Has infection determined to be from opioid/drug use and needed prolonged parenteral antimicrobial therapy * Gram positive organism as causal pathogen and expected to be sensitive to oritavancin * Deemed to be clinically stable for discharge (i.e no need for surgical intervention, with stable vital signs,afebrile and bacteremia cleared if present at admission for at least 72 hours) * Not on opioid agonist therapy at admission to hospital and willing to initiate medication for opioid use disorder, which includes methadone/suboxone * Willing and able to follow up for MOUD in colocated clinic site * If female, the patient is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use at least 2 highly effective methods of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods, abstinence) for the duration of the study until 60 days after study drug administration, or male partner sterilization alone Exclusion Criteria: * Known immediate hypersensitivity to oritavancin or glycopeptides * Decompensated liver disease (Childs Pugh B or C) or Stage IV/V chronic kidney disease or acute kidney injury with creatinine clearance \<30 * Unable to comply with research study visits * Poor venous access not allowing screening laboratory collection * Have any condition that the investigator considers a contraindication to study participation * Pregnant or breastfeeding woman * Require valve replacement surgery or have prosthetic material in body including prosthetic joints or non bioprosthetic valves. * Polymicrobial infection * Multisite infection- defined as \>2 different organ system involvement or non-contiguous sites of same organ system which may need different duration of antimicrobial therapy. * Lack of source control i.e lack of drainage of infected fluid collections, debridement of infected solid or necrotic tissue, removal of devices or foreign bodies, or definitive measures to correct anatomic derangements resulting in ongoing microbial contamination. This will be determined by investigator. * Need for subacute rehabilitation due to physical frailty either chronic, or from hospitalization. * Acute stroke during hospitalization. * Severe neutropenia- ANC \<500 or thrombocytopenia - platelet count \<50,000. * On prohibited concomitant medications
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacteremia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pilot testing of the emPath intervention to improve MOUD linkage and retention in durham, NC
- A safety net after jail: can checkups keep opioid treatment on track?
- Can AI and peer support close the opioid treatment gap?
- Peer mentors may help young adults stick with addiction treatment
- Can brain imaging unlock the secrets of opioid addiction?
- Digital toolkit aims to empower families in the opioid crisis